This antibody is specific for the TCR CD3 epsilon chain and can also be used to identify this subunit in immunoprecipitation and immunoblotting applications More
Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority More
The University of Edinburgh, in collaboration with the SNBTS, Roslin Institute Neuropathogenesis Unit, and the University of Strathclyde, has developed an antibody that can distinguish abnormal PrP (PrPSc) from the normal cellular form (PrPC) More
Displaying 1..10 of 29 -
per page
Next page
Order by